Brian Skorney

Stock Analyst at Baird

(2.14)
# 2,805
Out of 4,886 analysts
111
Total ratings
46.15%
Success rate
n/a
Average return

Stocks Rated by Brian Skorney

Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46$32
Current: $8.39
Upside: +281.41%
Sarepta Therapeutics
Jun 17, 2025
Maintains: Outperform
Price Target: $60$30
Current: $19.03
Upside: +57.65%
Soleno Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $102$105
Current: $85.26
Upside: +23.15%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300$255
Current: $134.46
Upside: +89.65%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652$587
Current: $547.75
Upside: +7.17%
Biohaven
Apr 28, 2025
Maintains: Outperform
Price Target: $60$57
Current: $13.94
Upside: +308.90%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50$55
Current: $50.25
Upside: +9.46%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95$100
Current: $111.06
Upside: -9.96%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $12.65
Upside: +137.15%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14$5
Current: $0.37
Upside: +1,255.01%
Maintains: Outperform
Price Target: $26$20
Current: $7.79
Upside: +156.90%
Initiates: Outperform
Price Target: $25
Current: $3.48
Upside: +618.39%
Maintains: Outperform
Price Target: $32$10
Current: $2.50
Upside: +300.00%
Reiterates: Underperform
Price Target: $215
Current: $297.00
Upside: -27.61%
Maintains: Outperform
Price Target: $157$180
Current: $128.74
Upside: +39.82%
Initiates: Outperform
Price Target: $28
Current: $4.44
Upside: +531.34%
Maintains: Outperform
Price Target: $52$62
Current: $29.38
Upside: +111.06%
Maintains: Outperform
Price Target: $34$39
Current: $8.74
Upside: +346.22%
Initiates: Outperform
Price Target: $63
Current: $31.42
Upside: +100.51%
Maintains: Neutral
Price Target: $280$325
Current: $466.36
Upside: -30.31%
Downgrades: Neutral
Price Target: $10
Current: $16.87
Upside: -40.72%
Initiates: Outperform
Price Target: $270
Current: $2.46
Upside: +10,875.61%
Downgrades: Neutral
Price Target: $18$6
Current: $3.18
Upside: +88.68%
Maintains: Outperform
Price Target: $600$300
Current: $1.85
Upside: +16,116.22%